RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)

被引：0
|
作者：
Garcia-Manero, G. [1 ]
Fenaux, P. [2 ]
Al-Kali, A. [3 ]
Baer, M. R. [4 ]
Sekeres, M. [5 ]
Roboz, G. [6 ]
Gaidano, G. [7 ]
Scott, B. [8 ]
Greenberg, P. [9 ]
Platzbecker, U. [10 ]
Steensma, D. P. [11 ]
Kambhampati, S. [12 ]
Kreuzer, K. A. [13 ]
Godley, L. [14 ]
Collins, R. [15 ]
Atallah, E. [16 ,17 ]
Azarnia, N. [18 ]
Petrone, M. E. [19 ]
Snyder, B. R. [20 ]
Maniar, M. [21 ]
Silverman, L. R. [22 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Hosp St Louis, Serv Hematol Seniors, Paris, France
[3] Mayo Clin, Dept Hematol, Rochester, MN USA
[4] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Cleveland Clin, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA
[6] Weill Cornell Med Coll, Leukemia Serv, New York, NY USA
[7] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Novara, Italy
[8] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[9] Stanford Med Sch, Dept Med Hematol, Stanford, CA USA
[10] Univ Klinikum Dresden, Med Klin & Poliklin 1, Dresden, Germany
[11] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[12] Univ Kansas, Med Ctr, Dept Internal Med, Westwood, KS USA
[13] Univ Klinikum Koln, Dept Internal Med, Cologne, Germany
[14] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[15] Univ Texas Dallas, Dept Internal Med, Dallas, TX 75230 USA
[16] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[17] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[18] Onconova Therapeut Inc, Dept Biometr, Newtown, PA USA
[19] Onconova Therapeut Inc, Dept Pharmacovigilance & Med & Sci Commun, Newtown, PA USA
[20] Onconova Therapeut Inc, Dept Med & Sci Commun, Newtown, PA USA
[21] Onconova Therapeut Inc, Prod Dev Dept, Newtown, PA USA
[22] Icahn Sch Med Mt Sinai, Dept Leukemia, New York, NY 10029 USA
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30113-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
112
引用
收藏
页码：S57 / S58
页数：2
相关论文
共 50 条
  • [1] Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    Al-Kali, Aref
    Baer, Maria R.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    Gaidano, Gianluca
    Scott, Bart L.
    Greenberg, Peter L.
    Platzbecker, Uwe
    Steensma, David P.
    Kambhampati, Suman
    Kreuzer, Karl-Anton
    Godley, Lucy A.
    Collins, Robert
    Atallah, Ehab
    Wilhelm, Francois
    Wilhelm, Isabelle E.
    Azarnia, Nozar
    Maniar, Manoj
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [2] INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs) Study design informed by subgroup analyses of ONTIME.
    Garcia-Manero, Guillermo
    Al-Kali, Aref
    Baer, Maria R.
    Robor, Gail J.
    Platzbecker, Uwe
    Kambhampati, Suman
    Godley, Lucy A.
    Collins, Robert
    Shammo, Jamile M.
    Santini, Valeria
    Raza, Azra
    Silverman, Lewis R.
    Azarnia, Nozar
    Fruchtman, Steven M.
    Snyder, Barbara R.
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)
    Silverman, Lewis R.
    Fenaux, Pierre
    Al-Kali, Aref
    Baer, Maria R.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    Gaidano, Gianluca
    Scott, Bart L.
    Greenberg, Peter L.
    Platzbecker, Uwe
    Steensma, David P.
    Kambhampati, Suman
    Kreuzer, Karl-Anton
    Godley, Lucy A.
    Collins, Robert
    Atallah, Ehab
    Navada, Shyamala C.
    Wilhelm, Francois
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [4] Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs)
    Mufti, Ghulam J.
    Silverman, Lewis R.
    Best, Steven
    Fructman, Steve
    Azarnia, Nozar
    Petrone, Michael E.
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
  • [5] MUTATIONAL PROFILE AND KARYOTYPIC ABNORMALITIES OF CLINICAL TRIAL PATIENTS WITH HIGHER-RISK MDS FOLLOWING FAILURE OF HYPOMETHYLATING AGENTS (HMAS): IMPACT ON RESPONSE TO RIGOSERTIB THERAPY
    Mufti, G. J.
    Best, S.
    Lea, N.
    Hellstrom-Lindberg, E.
    Silverman, L. R.
    Garcia-Manero, G.
    Azarnia, N.
    Petrone, M. E.
    Snyder, B. R.
    Gohring, G.
    LEUKEMIA RESEARCH, 2015, 39 : S57 - S57
  • [6] AVALIDATION OF A POST-HYPOMETHYLATING AGENT FAILURE (HMAF) PROGNOSTIC MODEL IN MDS PATIENTS TREATED WITH RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC)
    Nazha, A.
    Sekeres, M.
    Komrokji, R.
    Steensma, D.
    Kantarjian, H.
    Roboz, G.
    Fenaux, P.
    Prebet, T.
    Azarnia, N.
    Zbyszewski, P.
    Fruchtman, S.
    Santini, V.
    Silverman, L.
    Platzbecker, U.
    Garcia-Manero, G.
    LEUKEMIA RESEARCH, 2017, 55 : S147 - S148
  • [7] Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial
    Short, Nicholas J.
    Garcia-Manero, Guillermo
    Naqvi, Kiran
    Kornblau, Steven
    Takahashi, Koichi
    Montalban-Bravo, Guillermo
    Khouri, Rita
    Andreeff, Michael
    Konopleva, Marina
    DiNardo, Courtney D.
    Alvarado, Yesid
    Ghosn, Marie
    Estrov, Zeev
    Bose, Prithviraj
    Islam, Rubiul
    Dong, Xiao
    Cortes, Jorge E.
    Kantarjianand, Hagop M.
    Jabbour, Elias J.
    BLOOD, 2017, 130
  • [8] BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?
    Silverman, L. R.
    Fenaux, P.
    Al-Kali, A.
    Baer, M. R.
    Sekeres, M.
    Roboz, G.
    Gaidano, G.
    Scott, B.
    Greenberg, P.
    Platzbecker, U.
    Steensma, D. P.
    Kambhampati, S.
    Kreuzer, K. A.
    Godley, L.
    Collins, R.
    Atallah, E.
    Navada, S. C.
    Azarnia, N.
    Garcia-Manero, G.
    LEUKEMIA RESEARCH, 2015, 39 : S44 - S45
  • [9] Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy
    Mufti, Ghulam J.
    Best, Steven
    Lea, Nicholas
    Silverman, Lewis R.
    Garcia-Manero, Guillermo
    Azarnia, Nozar
    Wilhelm, Francois
    Goehring, Gudrun
    BLOOD, 2014, 124 (21)
  • [10] Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Adesanya, Afoluso Ronnee
    Zbyszewski, Patrick S.
    Woodman, Richard C.
    Fenaux, Pierre
    Silverman, Lewis R.
    BLOOD, 2019, 134
12345